Peter Verdult

Peter Verdult Analyst Performance

Managing Director - Pharmaceuticals analyst at BNP Paribas Exane

Peter Verdult is a stock analyst at BNP Paribas Exane in the healthcare sector, covering 4 publicly traded companies. Over the past year, Peter Verdult has issued 2 stock ratings, including buy and hold recommendations. While full access to Peter Verdult's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Peter Verdult's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
6 Last 1 Years
Buy Recommendations
66.67% 4 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy16.7%1 ratings
Buy50.0%3 ratings
Hold33.3%2 ratings
Sell0.0%0 ratings

Out of 6 total stock ratings issued by Peter Verdult at BNP Paribas Exane, the majority (50.0%) have been Buy recommendations, followed by 33.3% Hold and 16.7% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NYSE
75.0% of companies on NYSE
3 companies
NASDAQ
25.0% of companies on NASDAQ
1 company

Peter Verdult, an analyst at BNP Paribas Exane, currently covers 4 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Healthcare
4 companies
100.0%

Peter Verdult of BNP Paribas Exane specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
4 companies
100.0%

Peter Verdult's Ratings History at BNP Paribas Exane

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Sanofi stock logo
SNY
Sanofi
11/9/2026Upgrade$47.04$57.00Outperform
Sanofi stock logo
SNY
Sanofi
4/20/2026Downgrade$48.06$50.00Neutral
AstraZeneca Plc stock logo
AZN
AstraZeneca
4/15/2025Initiated Coverage$135.02$150.00Outperform
GSK PLC Sponsored ADR stock logo
GSK
GSK
4/15/2025Initiated Coverage$35.63$35.25Neutral
Sanofi stock logo
SNY
Sanofi
4/15/2025Initiated Coverage$51.07$65.00Outperform
Novartis AG stock logo
NVS
Novartis
4/15/2025Upgrade$109.66Strong-Buy